Article Information
History
- March 1, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Helen Ward1,2,4,5,*,#,
- Graham Cooke3,4,5,*,
- Matthew Whitaker1,
- Rozlyn Redd1,
- Oliver Eales1,2,
- Jonathan C Brown3,4,
- Katharine Collet1,
- Emily Cooper1,
- Anna Daunt,
- Kathryn Jones1,5,
- Maya Moshe3,
- Michelle Willicombe3,
- Sophie Day1,5,
- Christina Atchison1,
- Ara Darzi4,6,
- Christl A Donnelly1,2,7,
- Steven Riley1,2,
- Deborah Ashby1,
- Wendy S Barclay3 and
- Paul Elliott1,4,5,8,9,10
- 1School of Public Health, Imperial College London, UK
- 2MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, UK
- 3Department of Infectious Disease, Imperial College London, UK
- 4Imperial College Healthcare NHS Trust, UK
- 5National Institute for Health Research Imperial Biomedical Research Centre, UK
- 6Institute of Global Health Innovation at Imperial College London, UK
- 7Department of Statistics, University of Oxford, UK
- 8MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK
- 9Health Data Research (HDR) UK London at Imperial College
- 10UK Dementia Research Institute at Imperial College
- ↵#Corresponding authors: Prof Helen Ward, h.ward{at}imperial.ac.uk, Prof Graham Cooke, g.cooke{at}imperial.ac.uk, Prof Paul Elliott, p.elliott{at}imperial.ac.uk
↵* Contributed equally
Posted March 01, 2021.
REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England
